Business Description
Veru Inc
NAICS : 541713
SIC : 2834
ISIN : US92536C2026
Total Employee Number:
20Compare
Compare
Traded in other countries / regions
VERU.USAFMW0.Germany Index Membership
Russell 3000Russell 2000Russell 2000Russell 3000 IPO Date
1990-06-01Description
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 10.86 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.1 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.5 | |||||
3-Year EPS without NRI Growth Rate | 39.8 | |||||
3-Year FCF Growth Rate | 30.2 | |||||
3-Year Book Growth Rate | -50.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.83 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.07 | |||||
9-Day RSI | 53.02 | |||||
14-Day RSI | 54.32 | |||||
3-1 Month Momentum % | 3.59 | |||||
6-1 Month Momentum % | -3.75 | |||||
12-1 Month Momentum % | -64.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.19 | |||||
Quick Ratio | 6.19 | |||||
Cash Ratio | 5.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.1 | |||||
Shareholder Yield % | -37.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -55.09 | |||||
ROA % | -38.65 | |||||
ROIC % | -193.69 | |||||
3-Year ROIIC % | -197.53 | |||||
ROC (Joel Greenblatt) % | -904.89 | |||||
ROCE % | -95.12 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.38 | |||||
Price-to-Tangible-Book | 1.73 | |||||
EV-to-EBIT | -0.72 | |||||
EV-to-EBITDA | -0.72 | |||||
EV-to-Forward-Revenue | 29.8 | |||||
EV-to-FCF | -0.78 | |||||
| Price-to-Net-Current-Asset-Value | 1.93 | |||||
| Price-to-Net-Cash | 2.14 | |||||
Earnings Yield (Greenblatt) % | -138.89 | |||||
FCF Yield % | -54.12 | |||||
Forward Rate of Return (Yacktman) % | 29.39 |
GF Valueâ„¢
Veru Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veru Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2026-12-17 08:00 | In 174 days | ||
| Annual report for 2026 | 2026-12-17 | In 173 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-17 | In 173 days | ||
| Third quarter earnings conference call for 2026 | 2026-08-12 08:00 | In 47 days | ||
| Third quarter earnings results for 2026 | 2026-08-12 | In 46 days | ||
| Second quarter earnings conference call for 2026 | 2026-05-13 08:00 | 2.27 (+2.25%) | ||
| Second quarter earnings results for 2026 | 2026-05-13 | 2.27 (+2.25%) | ||
| General meeting for 2026 | 2026-03-12 09:00 | 2.53 (+3.27%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 15:20 | 2.59 (-1.52%) | ||
| First quarter earnings conference call for 2026 | 2026-02-11 08:00 | 2.31 (-4.55%) |
Show
Entries
Guru Commentaries on NAS:VERU
No articles.
Press Release
Articles on Veru Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers